NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $10.56
Forecasted Upside: 134.20 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
1 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$4.51 As of 07/23/2021 01:00 AM ET

▼ -0.13 (-2.80%)

1 month | 3 months | 12 months

Get New Zynerba Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ZYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYNE

^$10.56

▲ +134.20% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $10.56, with a high forecast of $18.00 and a low forecast of $7.25. The average price target represents a 134.20% upside from the last price of $4.51.

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Zynerba Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/30/2020

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/29/2020

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/28/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/26/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/24/2021

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/24/2021

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/23/2021

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/6/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$6.00 ➝ $8.00	High
3/10/2021	Roth Capital	Lower Price Target	Buy	$8.00 ➝ $7.25	High
2/5/2021	Canaccord Genuity	Reiterated Rating	Buy	$18.00	High
1/20/2021	Canaccord Genuity	Reiterated Rating	Buy		Medium
12/21/2020	HC Wainwright	Lower Price Target	Buy	$12.00 ➝ $9.00	Low
9/14/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium
8/10/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium
7/1/2020	HC Wainwright	Reiterated Rating	Buy	$12.00	Medium
7/1/2020	Canaccord Genuity	Lower Price Target	Buy	$18.00 ➝ $12.00	High
7/1/2020	Needham & Company LLC	Downgrade	Buy ➝ Hold		Medium
7/1/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$24.00 ➝ $8.00	Medium
6/29/2020	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$26.00	Medium
5/28/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$21.00 ➝ $24.00	High
5/22/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$12.00 ➝ $21.00	High
4/16/2020	Needham & Company LLC	Reiterated Rating	Buy	$16.00	High
2/20/2020	HC Wainwright	Reiterated Rating	Buy		Low
12/31/2019	Roth Capital	Initiated Coverage	Buy	$12.00	High
10/21/2019	Needham & Company LLC	Initiated Coverage	Buy	$18.00	High
9/18/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$26.00	High
9/16/2019	Jefferies Financial Group	Reiterated Rating	Hold	$11.00	Low
6/28/2019	Canaccord Genuity	Set Price Target	Buy	$18.00	High
5/31/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$12.00 ➝ $22.00	Medium
5/30/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$26.00	Medium
5/6/2019	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$26.00	Low
4/30/2019	Roth Capital	Initiated Coverage	Buy	$36.00	High
4/22/2019	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$8.09	High
3/18/2019	HC Wainwright	Reiterated Rating	Buy		High
3/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$11.00	Medium
12/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$21.00	High
12/5/2018	Cantor Fitzgerald	Set Price Target	Buy	$21.00	Medium
11/13/2018	HC Wainwright	Set Price Target	Buy	$23.00	High
10/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Medium
9/21/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$21.00	Medium
8/6/2018	HC Wainwright	Set Price Target	Buy	$23.00	High
8/3/2018	Canaccord Genuity	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $15.00	High
8/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$20.00	High
7/13/2018	HC Wainwright	Set Price Target	Buy	$23.00	High
7/13/2018	Canaccord Genuity	Set Price Target	Buy	$18.00	High
7/5/2018	Canaccord Genuity	Reiterated Rating	Buy	$18.00	High
7/5/2018	HC Wainwright	Reiterated Rating	Buy	$23.00	High
7/5/2018	Cantor Fitzgerald	Set Price Target	Buy	$20.00	High
5/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$20.00	Medium
5/8/2018	Oppenheimer	Reiterated Rating	Hold		Low
4/25/2018	Cantor Fitzgerald	Set Price Target	Buy	$20.00	Low
4/16/2018	HC Wainwright	Set Price Target	Buy	$23.00	Medium
3/13/2018	Seaport Global Securities	Reiterated Rating	Buy		Low
3/13/2018	Oppenheimer	Reiterated Rating	Hold		Medium
3/13/2018	HC Wainwright	Set Price Target	Buy	$23.00	Medium
3/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$20.00	Medium
3/6/2018	HC Wainwright	Set Price Target	Buy	$23.00	High
3/5/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$17.00	High
2/1/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$23.00	Medium
1/29/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy ➝ Buy	$25.50	High
1/26/2018	Seaport Global Securities	Initiated Coverage	Buy ➝ Buy	$16.00	High
1/3/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High
1/3/2018	Oppenheimer	Reiterated Rating	Hold		High
12/4/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High
12/4/2017	Canaccord Genuity	Set Price Target	Outperform ➝ Buy	$15.00 ➝ $18.00	High
11/20/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	N/A
11/14/2017	Oppenheimer	Reiterated Rating	Hold		N/A
11/14/2017	Piper Jaffray Companies	Boost Price Target		$16.00 ➝ $20.00	N/A
10/2/2017	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$4.00 ➝ $17.00	Low
10/1/2017	Roth Capital	Set Price Target	Buy	$15.00	Medium
9/29/2017	Oppenheimer	Reiterated Rating	Hold		High
9/29/2017	Canaccord Genuity	Boost Price Target	Buy	$9.00 ➝ $15.00	High
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$4.00	High
9/28/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$7.00 ➝ $16.00	High
8/18/2017	Canaccord Genuity	Set Price Target	Buy	$35.00 ➝ $9.00	Low
8/15/2017	CIBC	Reiterated Rating	Outperform ➝ Market Perform		Low
8/15/2017	Roth Capital	Upgrade	Neutral ➝ Buy	$15.00	Low
8/15/2017	HC Wainwright	Set Price Target	Hold	$7.00	Low
8/15/2017	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$12.00 ➝ $7.00	Low
8/14/2017	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
8/14/2017	Cantor Fitzgerald	Set Price Target	Hold	$4.00	High
8/14/2017	Maxim Group	Reiterated Rating	Hold		High
8/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$32.00 ➝ $12.00	Medium
8/8/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$28.00	High
8/8/2017	Roth Capital	Downgrade	Buy ➝ Neutral	$30.00 ➝ $7.00	Medium
8/8/2017	HC Wainwright	Downgrade	Buy ➝ Neutral	$30.00 ➝ $7.00	High
8/7/2017	Oppenheimer	Set Price Target	Buy	$8.00	High
8/7/2017	Maxim Group	Downgrade	Buy ➝ Hold		High
8/7/2017	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$28.00 ➝ $4.00	High
8/7/2017	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$42.00 ➝ $7.00	High
8/1/2017	Cantor Fitzgerald	Set Price Target	Buy	$28.00	High
8/1/2017	Maxim Group	Set Price Target	Buy	$32.00	High
8/1/2017	HC Wainwright	Set Price Target	Buy	$30.00	High
7/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$32.00	Medium
6/26/2017	Maxim Group	Set Price Target	Buy	$32.00	N/A
6/10/2017	Roth Capital	Set Price Target	Buy	$30.00	High
6/8/2017	Cantor Fitzgerald	Set Price Target	Buy	$28.00	Low
6/8/2017	Maxim Group	Reiterated Rating	Buy	$32.00	Low
5/25/2017	Jefferies Financial Group	Reiterated Rating	Buy	$32.00	High
5/13/2017	Canaccord Genuity	Set Price Target	Buy	$35.00	Low
5/13/2017	Roth Capital	Set Price Target	Buy	$30.00	Low
5/9/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$28.00	High
4/1/2017	Oppenheimer	Set Price Target	Buy	$29.00	Low
3/28/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $30.00	High
3/27/2017	Cantor Fitzgerald	Set Price Target	Buy	$28.00	High
3/20/2017	Roth Capital	Boost Price Target	Buy	$25.00 ➝ $30.00	Low
3/13/2017	Roth Capital	Set Price Target	Buy	$25.00	Low
3/13/2017	Maxim Group	Reiterated Rating	Buy	$32.00	Medium
2/23/2017	Maxim Group	Initiated Coverage	Buy ➝ Buy	$32.00	N/A
1/5/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$28.00	N/A
12/21/2016	Cantor Fitzgerald	Initiated Coverage	Overweight	$28.00	N/A
12/21/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$42.00	N/A
12/18/2016	Oppenheimer	Set Price Target	Buy	$29.00	N/A
12/16/2016	HC Wainwright	Reiterated Rating	Buy	$22.00	N/A
12/6/2016	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$32.00	N/A
11/15/2016	HC Wainwright	Reiterated Rating	Buy		N/A
10/7/2016	HC Wainwright	Initiated Coverage	Buy	$22.00	N/A
9/7/2016	Canaccord Genuity	Reiterated Rating	Buy	$35.00	N/A
9/6/2016	Roth Capital	Set Price Target	Buy	$25.00	N/A
8/16/2016	Canaccord Genuity	Reiterated Rating	Buy	$35.00	N/A
8/16/2016	Canaccord Genuity	Set Price Target	Buy	$35.00	N/A
8/12/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$42.00	N/A
7/26/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$42.00	N/A

(Data available from 7/23/2016 forward)

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Today's Range

Now: $4.51

$4.50

$4.65

50 Day Range

MA: $5.18

$4.49

$5.98

52 Week Range

Now: $4.51

$3.15

$9.00

Volume

471,024 shs

Average Volume

3,176,493 shs

Market Capitalization

$186.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Zynerba Pharmaceuticals?

The following sell-side analysts have issued reports on Zynerba Pharmaceuticals in the last year: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for ZYNE.

What is the current price target for Zynerba Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Zynerba Pharmaceuticals in the last year. Their average twelve-month price target is $10.56, suggesting a possible upside of 134.2%. Canaccord Genuity has the highest price target set, predicting ZYNE will reach $18.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $7.25 for Zynerba Pharmaceuticals in the next year.
View the latest price targets for ZYNE.

What is the current consensus analyst rating for Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYNE will outperform the market and that investors should add to their positions of Zynerba Pharmaceuticals.
View the latest ratings for ZYNE.

What other companies compete with Zynerba Pharmaceuticals?

Other companies that are similar to Zynerba Pharmaceuticals include G1 Therapeutics, OrganiGram, Pharming Group, Kadmon, IDEAYA Biosciences, Epizyme, AnaptysBio, Merus, Rigel Pharmaceuticals, Syndax Pharmaceuticals, Affimed, Seres Therapeutics, Emisphere Technologies, Sesen Bio and Karyopharm Therapeutics.

How do I contact Zynerba Pharmaceuticals' investor relations team?

Zynerba Pharmaceuticals' physical mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company's listed phone number is 484-581-7505 and its investor relations email address is [email protected] The official website for Zynerba Pharmaceuticals is www.zynerba.com.